Document Detail

Specific CD4 down-modulating compounds with potent anti-HIV activity.
MedLine Citation:
PMID:  12960237     Owner:  NLM     Status:  MEDLINE    
Despite the availability of the current clinically approved anti-HIV drugs, new classes of effective antiviral agents are still urgently needed to combat AIDS. A promising approach for drug development and vaccine design involves targeting research on HIV-1 entry, a multistep process that comprises viral attachment, coreceptor interactions, and fusion. Determination of the viral entry process in detail has enabled the design of specific agents that can inhibit each step in the HIV entry process. Therapeutic agents that interfere with the binding of the HIV envelope glycoprotein gp120 to the CD4 receptor (e.g., PRO 542, PRO 2000, and CV-N) or the coreceptors CCR5 and CXCR4 (e.g., SCH-C and AMD3100) are briefly outlined in this review. The anti-HIV activity of cyclotriazadisulfonamides, a novel class of compounds with a unique mode of action by down-modulating the CD4 receptor in lymphocytic and monocytic cells, is especially highlighted. On the basis of the successful results of T-20, the first approved entry inhibitor, the development of effective antiretrovirals that block HIV entry will certainly be further encouraged.
Kurt Vermeire; Dominique Schols
Related Documents :
16737697 - Silencing of hiv by hairpin-loop-structured dna oligonucleotide.
21776297 - Major hiv resistance mutations in untreated romanian patients.
21910117 - Survey on hiv risk perception and sexual behaviours among seafarers.
22131907 - Hiv, gender, race, sexual orientation, and sex work: a qualitative study of intersectio...
6254137 - Maternal transmission of hepatitis b surface antigen in patients with hepatocellular ca...
10930147 - Importance of protease inhibitor plasma levels in hiv-infected patients treated with ge...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2003-08-01
Journal Detail:
Title:  Journal of leukocyte biology     Volume:  74     ISSN:  0741-5400     ISO Abbreviation:  J. Leukoc. Biol.     Publication Date:  2003 Nov 
Date Detail:
Created Date:  2003-11-03     Completed Date:  2004-01-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8405628     Medline TA:  J Leukoc Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  667-75     Citation Subset:  IM    
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-HIV Agents / pharmacology*,  therapeutic use
Antigens, CD4 / drug effects*
Cell Line
HIV Envelope Protein gp120 / drug effects
HIV-1 / drug effects,  physiology*
Lymphocytes / immunology
Monocytes / immunology
Receptors, HIV / physiology
Reg. No./Substance:
0/Anti-HIV Agents; 0/Antigens, CD4; 0/HIV Envelope Protein gp120; 0/Receptors, HIV

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunodeficiency virus exploitation of dendritic cells in the early steps of infection.
Next Document:  The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection.